# John F. Seymour

Source: https://onco.cc/people/john-seymour/  
OnCo record `john-seymour` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led MURANO, which established venetoclax plus rituximab as fixed-duration therapy for relapsed CLL.

## Summary

John Seymour was principal investigator of MURANO, the trial showing two years of venetoclax plus rituximab dramatically improves progression-free and overall survival compared with bendamustine-rituximab in relapsed CLL, the first randomised proof of venetoclax's benefit and the first fixed-duration targeted regimen. He co-led the first-in-human venetoclax studies with the Melbourne group that discovered BCL2 inhibition and leads haematology at Peter Mac.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: cll; venetoclax; australia
- Role: Director of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital
- Specialisms: Chronic lymphocytic leukaemia; Venetoclax; Lymphoma; BCL2 inhibition

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Seymour%20JF%5BAuthor%5D%20venetoclax%20MURANO

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- targets: [BCL-2](https://onco.cc/targets/bcl2/), [CD20](https://onco.cc/targets/cd20/)
- drugs: [Venetoclax](https://onco.cc/drugs/venetoclax/)
- institutions: [Peter MacCallum Cancer Centre](https://onco.cc/institutions/peter-mac/)
- key papers: [MURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL](https://onco.cc/key-papers/paper-murano-venetoclax-rituximab-nejm-2018/)
- trials: [MURANO](https://onco.cc/trials/murano/)

---
JSON: https://onco.cc/api/v1/entities/john-seymour.json